<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952365</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-38495</org_study_id>
    <nct_id>NCT02952365</nct_id>
  </id_info>
  <brief_title>Tissue Sealant Use in LASIK Enhancement Surgery</brief_title>
  <official_title>A Prospective Evaluation of Tissue Sealant to Prevent Epithelial Ingrowth in Repeat LASIK Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the use of prophylactic tissue sealant to prevent&#xD;
      epithelial ingrowth from gaining access under a LASIK flap with repeat LASIK surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will have a comprehensive eye examination once they express an interest in the&#xD;
      study. This includes a slit lamp examination of the front of the eye and a dilated&#xD;
      fundoscopic examination of the back of the eye. If there is any pathology noted that would&#xD;
      exclude the participant from the study, then the participant will be informed and given an&#xD;
      appropriate referral. If the participant is deemed appropriate for the study after a&#xD;
      comprehensive examination included computerized videokeratography, then they can be enrolled.&#xD;
      The participant will undergo LASIK flap lift eye surgery.&#xD;
&#xD;
      Tissue sealant will be applied at to the edge of the LASIK flap at the conclusion of the&#xD;
      surgery. A bandage contact lens will also be placed. The bandage contact lens is used in the&#xD;
      usual and customary fashion as in non-study LASIK flap lift surgery.&#xD;
&#xD;
      The participants will be seen on the day of surgery, post op day one, one month, and three&#xD;
      months. The participant will receive topical antibiotics in each eye for one week following&#xD;
      the procedure. The participant will receive pred forte 1% ophthalmic drops for one week after&#xD;
      treatment. The participant will also receive vigamox ophthalmic drops for seven days after&#xD;
      treatment. All of this is within the usual and customary standard of care for the treatment&#xD;
      of participants undergoing LASIK surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slit lamp examination</measure>
    <time_frame>Three months</time_frame>
    <description>Presence of epithelial ingrowth under LASIK flap</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Epithelial Ingrowth</condition>
  <arm_group>
    <arm_group_label>Eyes undergoing LASIK enhancement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tissue sealant</intervention_name>
    <description>Application of tissue sealant on eyes undergoing LASIK enhancement</description>
    <arm_group_label>Eyes undergoing LASIK enhancement</arm_group_label>
    <other_name>ReSure sealant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 21 and older&#xD;
&#xD;
          -  Subjects with healthy eyes&#xD;
&#xD;
          -  Subjects who have previously undergone LASIK surgery&#xD;
&#xD;
          -  Subjects with residual refractive error.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under the age of 21.&#xD;
&#xD;
          -  Subjects with excessively thin corneas.&#xD;
&#xD;
          -  Subjects with topographic evidence of keratoconus.&#xD;
&#xD;
          -  Subjects with ectatic eye disorders.&#xD;
&#xD;
          -  Subjects with autoimmune diseases.&#xD;
&#xD;
          -  Subjects who are pregnant or nursing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edward E Manche, MD</last_name>
    <phone>650 498-7020</phone>
    <email>lasik.manche@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Schwartz</last_name>
    <phone>650 498-7020</phone>
    <email>lschwartz@stanfordhealthcare.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward E Manche, MD</last_name>
      <phone>650-498-7020</phone>
    </contact>
    <investigator>
      <last_name>Edward E Manche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>LASIK, Ingrowth, Tissue sealant</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>November 15, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

